Oculis Holding AG

Oculis Holding AG is a clinical-stage biopharmaceutical company focused on developing treatments for ophthalmic, neuro-ophthalmic, and neurological diseases. Its current pipeline centers on OCS-01, a topical retinal candidate for diabetic macular edema; OCS-02, a topical biologic candidate for dry eye disease; and OCS-05, a neuroprotective candidate being studied for conditions such as acute optic neuritis and other disorders affecting vision and the nervous system. The company’s work is aimed at addressing unmet medical needs in eye care through formulations designed for local delivery and patient convenience. Oculis Holding AG operates as a global life sciences business with activities in Switzerland and other international markets, serving the broader biotechnology sector through research, clinical development, and disease-specific therapeutic innovation.

Sector

Healthcare

Industry

Biotechnology

CEO

Dr. Riad Sherif M.B.A., M.D.

Employees

60

Headquarters

Zug, Switzerland

Website

oculis.com